Business Wire

SERES

13.1.2023 14:31:38 CET | Business Wire | Press release

Share
SERES Introduces Europe to SERES 5, Its Premium Sport e-SUV

For 36 years, SERES, a subsidiary of the eponymous Chinese group, has positioned itself as a premium smart e-vehicle brand. After five years of development and testing, the company is officially launching the cutting-edge, high-performing, high-tech SERES 5 in Europe. Available in three models (Standard version 2WD, Premium version 4WD, Flagship version 4WD) the SERES 5 is a sporty, premium e-SUV that blazes a new trail by combining the best of everything: design, smart driving, power, range and comfort. From January 14 to 22, visitors to the Brussels Motor Show will get an exclusive sneak peek at the premium sport E-SUV before it goes on sale in March.

Natural Aesthetics of Life
Many people sat up and took notice when the SERES 5 concept was unveiled in Silicon Valley. In particular, its design caught their eye as SERES5 is inspired by nature with flexibility, purity and vitality. Special attention was paid to the nature-inspired aesthetics (Σ front face, willow-inspired window, Belt line mimics dolphin’s leaping). The roofline continuously and uninterruptedly descends to the trunk, giving the vehicle an ultra-low wind resistance, making it more dynamic and more energy efficient 1. The SERES 5 is available in 8 exterior colours and 5 interior ones that can be combined as desired.

Zero to 100 km/h in 3.7 seconds and a range up to 530 km
Behind its premium design lies an amazing driving experience enhanced by a performance worthy of the market’s top models. The SERES 5 accelerates from 0 to 100 km/h in 3.7 seconds thanks to its front and rear motor peak power (430KW) and peak torque 960N.m.

To control acceleration and stabilize the vehicle, the chassis is mainly made of a strong, lightweight aluminium alloy. For a premium driving experience, a dual ball joint front double-wishbone front suspension enhances anti-roll performance and a multi-link trapezoidal arm type rear independent suspension improves stability.

The SERES 5 boasts an outstanding range. Its 80kWh lithium iron phosphate and 90 kWh semi solid state high performance batteries offer a significant power supply and high energy efficiency. Thus, on a single charge the 2WD model can travel 500 km WLTP and the 4WD can cover 530 km WLTP. They are compatible with 95% of the charging systems available in Europe. Moreover, SERES 5 includes a smart fast charging system: a quick recharge to shorten the waiting time on the way and, on camping ground, a V2L function can provide power to many travel appliances such as induction cookers and coffee makers, while the V2V function can also help charge other people’s EV’s in emergency.

The SUV is also equipped with an industry leading permanent magnet motor: a little technological gem.

A safe, unparalleled driving experience
The SERES 5 also stands out for its 18 assisted-driving features, +300 smart voice assistants (8 active service reminders, 14 telephone operations, 17 navigation operations, 35 multimedia operations, ...), 3 smart scenarios (rest mode, temporary stop mode, camping mode) and over 20 "Smart Car Ecology" devices (on-line map, On-line music, car game, DAB digital radio).

As a safety feature, voice commands let the driver control everything from air conditioning to music while keeping both hands on the wheel and eyes on the road. The SERES 5 also has LFP batteries and, for the first time, a semi-solid battery as standard equipment that has undergone around 100 tests, with a long service life (100,000 km without degradation) and high peak power (430 KW). What’s more, the SERES 5 benefits from a five-level safety management system and has travelled the equivalent of 5.000.000 km in extreme conditions (cold, heat, high altitudes, etc.) to ensure optimal use. To provide the best of breed, the brand has also gathered a global supply chain system of experts (Astemo, Longhorn, Bosch, Valeo, Pirelli, BASF, …) around its SERES 5.

Finally in order to provide worry-free travel to its customers, SERES offers two outstanding warrantees: a 8 years (160.000 km) warranty for the battery, electric motor and electric control system and a 4 years (100.000 km) warranty for the vehicle. Besides, SERES 5 drivers will benefit from a 24hours emergency rescue road service, as well as online and offline customer services to all SERES valued customer.

Custom-made comfort for stress-free driving
SERES takes pride in putting technology to work for drivers and passengers with intelligent interiors geared to their needs. For example, instead of displaying all the features on a single central screen, three of them are arrayed around the driver to make the important messages visible while ensuring that the view is clear at every angle (HUD, 15.6” large central control screen, 12.3” LCD dashboard).

For a comfortable ride, the front seat can be adjusted in 12 different ways and is equipped with various settings such as ventilation, heating, memory, massage ... The SERES 5 also has two 40W wireless fast chargers (front and rear) to meet a wide variety of needs. The optional 85-inch deluxe panoramic skyline (field ratio 97.7%) offers a wide range of view while giving a unique impression of space. Lastly, new soundproofing and heat insulation materials keep the inside very quiet whatever the speed.

At the press conference, Mr. John Zhang, the chairman and founder of SERES Group emphasized that “In making SERES into a high-end, intelligent new energy vehicle brand, starting 2016, the group had consistently invested over 10% of its total revenue each year in Intelligent EV technologies. We have built industry 4.0 standard Intelligent factories, have developed and launched high-performance battery and range of other intelligent EV related products. Today these technologies are not only leading the sector in China but are considered to be on an advanced level on a global scale.”

The SERES 5 will be available from the brand's European sales network in March

Dimensions: 4710 x 1930 x 1620 mm
Standard version 2WD: from €63,9002
Premium version 4WD: from €67,900
Flagship version 4WD: from €74,900

1278 Cd drag coefficient
2 indicative prices for the German market

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye